<?xml version="1.0" encoding="UTF-8"?>
<p>Previous advances showed that telbivudine had no effects on human nucleotides stability or DNA synthesis.
 <sup>[
  <xref rid="R18" ref-type="bibr">18</xref>]
 </sup> Recently 1 meta-analysis including 26 studies, involving 3622 pregnant CHB women, showed that LdT, LAM, or tenofovir was effective to reduce MTCT rate with no significant increased adverse maternal or fetal events.
 <sup>[
  <xref rid="R19" ref-type="bibr">19</xref>]
 </sup> Consistently, our study indicated that telbivudine treatment during pregnancy in women with high viral load could effectively block MTCT.
 <sup>[
  <xref rid="R20" ref-type="bibr">20</xref>,
  <xref rid="R21" ref-type="bibr">21</xref>]
 </sup> Moreover, our study showed that perinatal LdT exposure did not affect the intelligent development of infants.
</p>
